Topical and systemic medications for the treatment of primary Sjögren's syndrome.
about
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and PerspectivesPrimary Sjögren's syndrome accompanied by pleural effusion: a case report and literature reviewNew pharmacological strategies in rheumatic diseasesIdentification of potential saliva and tear biomarkers in primary Sjögren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysis.Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.Sialendoscopic management of autoimmune sialadenitis: a review of literature.Rituximab in primary Sjögren's syndrome: a ten-year journey.Novel aspects of Sjögren's syndrome in 2012.Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-InteClinical Characteristics and Outcome of Primary Sjogren's Syndrome: A Large Asian Indian CohortTubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatmentPrimary Sjögren's syndrome related optic neuritis.The Core Pattern Analysis on Chinese Herbal Medicine for Sjögren's syndrome: A Nationwide Population-Based StudySjögren's syndrome - an update for dental practitioners.Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.Renal involvement in primary Sjögren's syndrome.Recommendations for the treatment of Sjögren's syndrome.T Helper 17 Cells in Primary Sjögren's Syndrome.Safety of treatments for primary Sjögren's syndrome.Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.Sarcoidosis: an update on current pharmacotherapy options and future directions.Optic neuritis as an initial presentation of primary Sjögren syndrome: A case report and literature reviewTocilizumab for refractory organising pneumonia associated with Sjögren's diseasePrimary and secondary surveys on epidemiology of Sjögren's syndrome in Japan.Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.Ro52- and Ro60-specific B cell pattern in the salivary glands of patients with primary Sjögren's syndrome.Adipose tissue is prominent in salivary glands of Sjögren's syndrome patients and appears to influence the microenvironment in these organs.Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.Autoimmune Diseases and Their Manifestations on Oral Cavity: Diagnosis and Clinical Management.Sjögren syndromePunctal occlusion in Sjögren's syndrome needs clarification
P2860
Q26859226-2181D727-2042-476E-A56E-8858D709ACFEQ28069521-3963407B-6A67-423A-AE22-ACC392138372Q28073763-B5396CCA-9099-44F6-88B9-F305621C515EQ30836404-D36E6A2F-587B-4BAB-946D-30ECF1F3DCF0Q33667694-11E59B1B-1040-4BAD-BED2-DFEEB7B57372Q33777026-B7FCE083-F915-4A93-A8DA-C3D6CCC2363BQ34432465-FDD691C7-4501-463B-90A2-6586F93C1F11Q34650103-6AC05F06-8B3F-4192-80A4-FF7DB585AD97Q35318424-15B88BDD-D822-4113-ADFE-D9FB34BEAEC4Q35824760-40E98F2A-9890-4490-BA22-E5227309D0D6Q35884577-030432E8-9F96-4199-B829-2BA12BDFF255Q37417860-BFFD2514-3E0D-489C-9A09-65DEE1DCA760Q37744586-70DF8B47-F727-4C9C-A508-E3B4F0C57319Q38051525-E28ADCD2-04D6-49CF-8490-B58A5444A59DQ38076460-BCAE2AC4-B5AA-4A51-9839-CD707E6A03AEQ38526786-C76138BF-E4E7-41EE-B955-1C314D4B3529Q38584878-01C11CF7-C116-4D4E-B052-37DEE9E00E40Q38693137-65E6729A-1D47-45F7-8E93-24FC7884E711Q38711144-754A4B86-8A42-48C1-AA5F-6534E00E91BEQ38795404-F062EAF4-C3D8-47D9-9401-8AA61F6757AAQ38798146-B8AC13A1-AC90-4C0B-83E5-FE52FD77076DQ39012087-8B8A17EC-880F-4784-8F44-538FBC708DDFQ40748901-256ED602-B194-4DE4-B1A3-087493BDE33FQ45282786-82FACFCF-7E0E-450B-9AB2-E5D34EA9B12BQ48088375-298BFA5A-E258-418A-B904-3D0222E28283Q48341665-648032BF-DC41-4EE1-A3D9-170D9F11E317Q49039960-BEC1231F-4BC2-41AE-AF40-9726E723ACC6Q50905593-87E42A05-61B7-4115-9ACD-66D2E8394C76Q53097366-35267D2A-AB30-4487-AA62-5B30BACE6985Q53194059-BAC2A092-6155-4B9B-AB62-C8379726603FQ55413268-69E7CB9C-413D-4041-A1B3-723A3C1EAB42Q55970262-ECC0D51A-317C-468F-B2C9-228F7B921D0FQ56907373-118FE44B-8B4D-40A2-93A5-3DECFE8D84DA
P2860
Topical and systemic medications for the treatment of primary Sjögren's syndrome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Topical and systemic medications for the treatment of primary Sjögren's syndrome.
@en
Topical and systemic medications for the treatment of primary Sjögren's syndrome.
@nl
type
label
Topical and systemic medications for the treatment of primary Sjögren's syndrome.
@en
Topical and systemic medications for the treatment of primary Sjögren's syndrome.
@nl
prefLabel
Topical and systemic medications for the treatment of primary Sjögren's syndrome.
@en
Topical and systemic medications for the treatment of primary Sjögren's syndrome.
@nl
P2860
P50
P356
P1476
Topical and systemic medications for the treatment of primary Sjögren's syndrome
@en
P2093
Athanasios G Tzioufas
Xavier Bosch
P2860
P2888
P304
P356
10.1038/NRRHEUM.2012.53
P407
P577
2012-05-01T00:00:00Z